European Commission President Ursula Von Der Leyen stated on Thursday that the vaccines might be accepted until the end of the calendar year, which might permit them to be distributed in Europe.
Ms Von der Leyen said earlier this week the commission hopes a deal with Moderna will soon be finalised.
BioNTech SE and Moderna Inc. could receive conditional European Union marketing authorization for their Covid-19 vaccines in the second half of next month, according to the head of the EU's executive arm, putting the bloc on track to start distributing the shots at the same time as the U.S.
The EU could pay more than $10 billion to buy hundreds of millions of doses of the vaccine jointly developed by Pfizer Inc. and BioNTech as well as that of CureVac NV, Reuters said Friday, citing an EU official it didn't name.
"After hard weeks with very, very slow progress, now we've seen in the last days better progress, more movement on important files", von der Leyen said.
Meanwhile on Friday, Pfizer and BioNTech have submitted an application to the United States authorities for emergency approval.
"There is a chance that we can receive approval from the U.S. or Europe or both regions this year still", said Sahin, who is also BioNTech's chief executive.
"We have all learned from our experience in the summer that the exit from a wave, in this case the exit from the first wave, is very hard and that the impact of lifting measures too hastily has had a very bad impact on the epidemiological situation in summer and fall", she said.
"It is clear that with a delay this is not going to limit the total amount but it is going to slow down delivery", he told AFP, in an interview.
This week, Moderna said its Covid-19 vaccine was 94.5% effective in a preliminary analysis of a large late-stage clinical trial.
The twin breakthroughs have lifted hopes for an end to a pandemic that has infected more than 56 million people and caused more than 1.3 million deaths worldwide since the virus first emerged in China late past year.